When it comes to our favorite income investments—8%+ yielding closed-end funds (CEFs)—there are a lot of misconceptions out there.

It’s critical that we put those right, because they’re causing some investors to miss out on CEFs, and the big (and often monthly) dividends they provide. And I know I don’t have to tell you that in turbulent times like these, high payouts like those are a lifesaver.

Two of the biggest misunderstandings surrounding these funds are:

• CEFs have higher expense ratios than passive funds, and …
• You’re better off to buy stocks, such as Microsoft (MSFT), direct, on the open market, than through CEFs.

Monthly bills are no problem for careful contrarian readers banking 9.1% yields in monthly divvies. Let’s discuss this rare but excellent dividend breed, the company or fund that pays monthly instead of quarterly.

Only 6% of dividend payers dish monthly. The rest are quarterly or annually, which will likely not be in time to cover your upcoming cell phone bill.

My monthly email from carrier Verizon arrives in a day or two. Another $267.26 will be debited from my account automatically on the 20th.

Fortunately, Verizon notes that there is “nothing I need to do” thanks to AutoPay. As if the automatic payment implies it costs any less money!… Read more

I often get asked about crypto. My response often surprises people: I don’t spend a lot of time thinking about it.

That might sound odd given crypto’s massive popularity (though many holders are no doubt regretting their buys these days, given the swan dive Bitcoin and its ilk have been on).

Nope, I avoid Bitcoin because I (and readers of my are interested in dividend income. And you won’t find any of that in crypto. Plus it’s far more volatile than we’d like. All of this is why, when we want tech exposure, we look to CEFs holding top-quality tech stocks.… Read more

Drug development will never be the same! AI is compressing time-to-market and extending the sales calendar for pharma. More profits from new medications. More new medications, too.

Many pharma and biotech stocks will boom as we enter the “sci-fi” stage of research and development. And this elite 8.8% dividend will directly benefit.

It typically takes 10 to 15 years to develop a new drug. Every month matters because patents last only 20 years. The faster a company gets a drug to market, the more months and years it enjoys with monopoly pricing power.

When patents expire, the generic versions hit the market.… Read more

Our favorite dividends are now on sale—but we still need to make sure we’re buying this dip the right way.

That means zeroing in on rich payers that not only throw off big divvies, but cushion our downside, too.

I’ve got two closed-end funds (CEFs) for you that do just that—and throw off rich 7%+ yields, too. And they avoid the deadly mistake most investors are making now.

Index Funds Pay Little, “Bargain” Techs Even Less

That mistake? Most investors are looking to beaten-down tech stocks (which pay zilch—or close to it!) or they’re grabbing a “plain vanilla” index fund, like the SPDR S&P 500 ETF Trust (SPY)—current yield: 1.1%

One-point-one-percent!… Read more

It never ceases to amaze me how many investors confuse investing with straight-up gambling.

Of course, we income investors know that gambling is a one-way ticket to losses (the house always wins, after all!). That’s why we always focus on long-term wealth creation (and a solid income stream) at my CEF Insider service, whose portfolio yields nearly 10% on average as I write this.

Nonetheless, with stocks having soared the way they have, it’s easier, even for normally prudent investors, to get caught up in dangerous speculation. That’s especially true when gambling seems to be everywhere these days.

Even though—a funny aside—gambling actually hasn’t grown as a percentage of Americans’ earnings in the last 25 years.… Read more

We contrarians follow Wall Street analysts because we like to fade their opinions!

When most say Buy, we are cautious. There is nobody left to upgrade these shares.

When they slap a Sell label, we are intrigued. So you’re saying the next rating change will be an upgrade?

These slippery suits rate most stocks Buys because, well, that’s the business. As we speak, 400 of the S&P 500 (!) is rated a Buy!

Even at All-Time Highs, Analysts Say 80% of the Market Is a Buy!

Source: S&P Global Market Intelligence

So let’s sift through the Holds and the Sells. Today we’ll sort through a four-pack yielding between 7.9% and 20.6%.… Read more

I’ve seen a lot more news stories trying to do something that seems a bit weird these days: stoke anger between generations.

I bring this up because it’s an example of why, when it comes to picking stocks (and 8%+ paying closed-end funds), we simply can’t trust the media anymore.

Why? Because many outlets are so focused on generating emotional responses (and the clicks that go with them) that they’ve gotten far away from what really matters: the real data behind what they’re saying.

With that in mind, we’re going to look at a data-driven indicator that tells us whether or not it’s a good time to buy.… Read more

Jerome Powell is preparing a wonderful holiday income dish for us.

The economy is running hot and he’s cutting rates anyway. Oh baby! “Lame Duck Jerry” is finally starting to cook.

But vanilla investors aren’t having it. They’re sprinting from the table! Recession fears dominate the headlines, even though the data scream otherwise.

The Atlanta Fed’s thermometer has GDP at a sizzling 4%. Four percent! In today’s AI-fueled, efficiency-obsessed economy, the old recession playbook simply doesn’t apply.

AI is eating traditional white-collar work. Business models from 2019 no longer apply in 2025. Some sectors are struggling while others hit new strides.… Read more

What a time to be a contrarian!

The economy is en fuego as AI boosts productivity (even if, yes, it’s cooling payrolls). Yet the mainstream crowd is hunkered down, terrified of an AI bubble.

That sets up some very attractive deals in 8%-paying closed-end funds (CEFs), many of which have gone on sale in the last few weeks.

2 “North Stars” Show Us What to Do Now

To get a feel for the setup in front of us, all we need to do is look at two things.

First, the Atlanta Fed’s GDPNow indicator, the most current economic “barometer” we have.… Read more